HHC
GHDX

Hutchin Hill Capital’s Genomic Health, Inc. GHDX Stock Holding History

Hutchin Hill Capital’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,900
Closed -$286K – 807
2017
Q3 		$286K Buy
+8,900
New +$281K 0.01% 645

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Hutchin Hill Capital's GHDX Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Genomic Health, Inc. (GHDX) in Q4 2017, closing a stake of 8,900 shares — an estimated $286K sold.

Hutchin Hill Capital first reported a position in GHDX in Q3 2017 and held it in 1 quarter. The position peaked at $286K in Q3 2017. 135 funds tracked by Wall St. Rank hold GHDX as of Q4 2017.

  • Hutchin Hill Capital reported no remaining Genomic Health, Inc. position as of Q4 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 8,900 Genomic Health, Inc. shares in Q4 2017, an estimated $286K.
  • Hutchin Hill Capital first reported a position in Genomic Health, Inc. in Q3 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Genomic Health, Inc. position peaked at $286K in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.